Literature DB >> 3514678

Evidence that prostacyclin modulates the vascular actions of calcium in man.

J L Nadler, M McKay, V Campese, J Vrbanac, R Horton.   

Abstract

Increases in extracellular calcium (Ca++) can alter vascular tone, and thus may result in increased blood pressure (Bp) and reduced renal blood flow (RBF). Ca++ can stimulate prostaglandin E2 (PGE2) and/or prostacyclin (PGI2) release in vitro, which may modulate Ca++ vascular effects. However, in man, the effect of Ca++ on PG release is not known. To study this, 14 volunteers received low-dose (2 mg/kg Ca++ gluconate) or high-dose (8 mg/kg) Ca++ infusions. The low-dose Ca++ infusion did not alter systemic or renal hemodynamics, but selectively stimulated PGI2, as reflected by the stable metabolite 6-keto-PGF1 alpha in urine (159 +/- 21-244 +/- 30 ng/g creatinine, P less than 0.02). The same Ca++ infusion given during cyclooxygenase blockade with indomethacin or ibuprofen was not associated with a rise in PGI2 and produced a rise in Bp and fall in RBF. However, sulindac, reported to be a weaker renal PG inhibitor, did not prevent the Ca++ -induced PGI2 stimulation (129 +/- 33-283 +/- 90, P less than 0.02), and RBF was maintained despite similar increases in Bp. The high-dose Ca++ infusion produced an increase in mean Bp without a change in cardiac output, and stimulated urinary 6-keto-PGF1 alpha to values greater than that produced by the 2-mg/kg Ca++ dose (330 +/- 45 vs. 244 +/- 30, P less than 0.05). In contrast, urinary PGE2 levels did not change. A Ca++ blocker, nifedipine, alone had no effect on Bp or urinary 6-keto-PGF1 alpha levels, but completely prevented the Ca++ -induced rise in Bp and 6-keto-PGF1 alpha excretion (158 +/- 30 vs. 182 +/- 38, P greater than 0.2). However, the rise in 6-keto-PGF1 alpha was not altered by the alpha 1 antagonist prazosin (159 +/- 21-258 +/- 23, P less than 0.02), suggesting that calcium entry and not alpha 1 receptor activation mediates Ca++ pressor and PGI2 stimulatory effects. These data indicate a new vascular regulatory system in which PGI2 modulates the systemic and renal vascular actions of calcium in man.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3514678      PMCID: PMC424475          DOI: 10.1172/JCI112431

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  51 in total

1.  Ionophores stimulate prostaglandin and thromboxane biosynthesis.

Authors:  H R Knapp; O Oelz; L J Roberts; B J Sweetman; J A Oates; P W Reed
Journal:  Proc Natl Acad Sci U S A       Date:  1977-10       Impact factor: 11.205

2.  Release of renal prostaglandin by catecholamines: relationship to renal endocrine function.

Authors:  P Needleman; J R Douglas; B Jakschik; P B Stoecklein; E M Johnson
Journal:  J Pharmacol Exp Ther       Date:  1974-02       Impact factor: 4.030

3.  The release of noradrenaline from sympathetic fibres in relation to calcium concentration.

Authors:  J H Burn; W R Gibbons
Journal:  J Physiol       Date:  1965-11       Impact factor: 5.182

4.  Indomethacin potentiates the vasoconstrictor actions of angiotensin II in normal man.

Authors:  P Negus; R L Tannen; M J Dunn
Journal:  Prostaglandins       Date:  1976-08

5.  Prostaglandins: modulators of renal function and pressor resistance in chronic liver disease.

Authors:  R D Zipser; J C Hoefs; P F Speckart; P K Zia; R Horton
Journal:  J Clin Endocrinol Metab       Date:  1979-06       Impact factor: 5.958

6.  Determination of cardiac output by transcutaneous continuous-wave ultrasonic Doppler computer.

Authors:  P A Chandraratna; M Nanna; C McKay; A Nimalasuriya; R Swinney; U Elkayam; S H Rahimtoola
Journal:  Am J Cardiol       Date:  1984-01-01       Impact factor: 2.778

7.  The effect of adrenergic stimulation on urinary prostaglandin E2 and 6 keto PGF1 alpha in man.

Authors:  J Nadler; R D Zipser; R Horton
Journal:  Prostaglandins       Date:  1983-10

8.  Effects of sulindac and ibuprofen in patients with chronic glomerular disease. Evidence for the dependence of renal function on prostacyclin.

Authors:  G Ciabattoni; G A Cinotti; A Pierucci; B M Simonetti; M Manzi; F Pugliese; P Barsotti; G Pecci; F Taggi; C Patrono
Journal:  N Engl J Med       Date:  1984-02-02       Impact factor: 91.245

9.  Stimulation of endothelial cell prostacyclin production by thrombin, trypsin, and the ionophore A 23187.

Authors:  B B Weksler; C W Ley; E A Jaffe
Journal:  J Clin Invest       Date:  1978-11       Impact factor: 14.808

10.  Prostaglandin synthesis by rat glomerular mesangial cells in culture. Effects of angiotensin II and arginine vasopressin.

Authors:  L A Scharschmidt; M J Dunn
Journal:  J Clin Invest       Date:  1983-06       Impact factor: 14.808

View more
  4 in total

Review 1.  Clinical pharmacokinetics of sulindac. A dynamic old drug.

Authors:  N M Davies; M S Watson
Journal:  Clin Pharmacokinet       Date:  1997-06       Impact factor: 6.447

2.  pH-dependent stimulation by Ca2+ of prostacyclin synthesis in rat aortic rings: effects of drugs and inorganic ions.

Authors:  J M Ritter; C E Frazer; G W Taylor
Journal:  Br J Pharmacol       Date:  1987-06       Impact factor: 8.739

3.  Dazoxiben-induced changes in the thromboxane/prostacyclin balance in the lateral cochlear wall of the guinea pig.

Authors:  A Ernst; C Taube; P Lotz; H J Mest
Journal:  Arch Otorhinolaryngol       Date:  1988

4.  Acute Interstitial Nephritis and Acute Tubular Injury Due to a Transdermal Loxoprofen Patch.

Authors:  Takahiro Shinzato; Ken Ohara; Hiroaki Kaminaga; Taro Sugase; Takahiro Masuda; Daisuke Nagata; Katano Saki; Yoshitaka Kinoshita; Taro Kubo; Toshihiro Shimizu; Koji Nanmoku; Takashi Yagisawa
Journal:  Intern Med       Date:  2020-11-01       Impact factor: 1.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.